KOD实时信号 | 通过Getagraph.com最大化利润

购买 107418 min ago

@ $4.87

发出时间: 15 Feb 2024 @ 02:51

回报率: -32.65%

上一信号: Feb 14 - 22:33

上一信号: 出售

回报率: -1.22 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	250 894
平均成交量	854 836
市值	172.28M
EPS	$0 ( 2024-03-28 )
下一个收益日期	( $-1.090 ) 2024-05-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.660
ATR14	$0.00200 (0.06%)

Insider Trading

Date	Person	Action	Amount	type
2023-06-30	Baker Bros. Advisors Lp	Buy	40 000	Non-Qualified Stock Options (right to buy)
2023-06-30	Yang Taiyin	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Profusek Robert	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Levy Richard S	Buy	40 000	Stock Option (Right to Buy)
2023-06-30	Dahiyat Bassil I	Buy	40 000	Stock Option (Right to Buy)

INSIDER POWER
96.07
Last 99 transactions
Buy: 3 824 931 \| Sell: 1 385 823

音量相关性

長: -0.29 (neutral)

短: -0.91 (very strong negative)

Signal:(40.23) Neutral

Kodiak Sciences Inc 相关性

10 最正相关
SONN	0.914
VERU	0.908
VNET	0.908
INFI	0.906
DZSI	0.903
LIVN	0.902
TCX	0.902
RYTM	0.901
PCVX	0.899
FNWB	0.897

10 最负相关
TYHT	-0.933
AAON	-0.913
GSHD	-0.912
PLPC	-0.905
ZGNX	-0.903
CNCE	-0.901
LNTH	-0.9
CPTA	-0.897
LMNR	-0.895
ADMS	-0.893

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kodiak Sciences Inc 相关性 - 货币/商品

-0.50
( neutral )

-0.06
( neutral )

0.00
( neutral )

0.12
( neutral )

-0.61
( weak negative )

0.55
( weak )

Kodiak Sciences Inc 财务报表

Annual	2023
营收:	$0
毛利润:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2023
营收:	$0
毛利润:	$-25.95M (0.00 %)
EPS:	$-4.97

FY	2022
营收:	$0
毛利润:	$-11.00M (0.00 %)
EPS:	$6 502.21

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-5.16

Financial Reports:

No articles found.

Kodiak Sciences Inc

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate to treat retinal diseases with an inflammatory component; and KSI-601, a triplet inhibitor for the treatment of dry AMD. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.